HSCT México

All immune cells in the body originate from a common progenitor, known as a hematopoietic stem cell (HSC) found in the bone marrow. As the HSC divides, it gives rise to a wide diversity of immune cell repertoire that all serve specific immune functions. Many of these immune cells, known as lymphocytes, are capable of recognizing and defending against foreign pathogens that enter the body.
For an, as yet, unknown reason, some of the lymphocyte immune cells develop a corrupted memory in which they become self-intolerant and attack & damage different cells and tissues of the body. In the same manner as normal cells divide, so does the mutant auto-toxic cell clone, giving rise to a large population of autoreactive cells that mediate damage of different normal structures.
Autoimmune damage of insulin-producing cells of the pancreas causes type I diabetes mellitus. This is the fundamental mechanism that underlies autoimmune disease and using chemotherapy to eliminate these self-intolerant auto-toxic lymphocytes is the key to also halting the underlying autoimmune disease. The immune cells eliminated from the body are eventually replaced with new immune cells created in the bone marrow, which do not contain toxic corrupted cells, thereby halting the underlying disease activity.

Patients with a confirmed positive diagnosis of the following disorder are eligible for HSCT treatment: Type I Diabetes
Patients´ date of diagnosis must be less than six months at the time of starting treatment.
Patients must be free of contraindicating health factors as determined by the clinic HSCT physician, and be deemed suitably healthy to safely tolerate the treatment.
Patients may be considered for treatment based upon individual health status and must be at least 8 years of age.
Patient must have a Pancreatic reserve demonstrated by peptide C equal to or greater than 1 in the sustacal test.
Patient must have Anti-GAD, Anti-IA2 or Anti-insulin positive antibodies
Patient has to be able to travel to and remain in Monterrey, Mexico during a 28-day period, accompanied by a caregiver.
If a medical condition appears in the preliminary evaluations performed by our specialists that impedes the patient from receiving the transplant, the patient will be refunded. The only charges that will apply will be the ones consumed up to that point, such as, transportation, partial lodging and the evaluations performed.
Treatment must be fully paid two months prior to schedule treatment.